Raising up to $7,000,000 at $0.20. The Enterprise Value at IPO will be $23m.
Firebrick is an Australian pharmaceutical company with a patented product, Nasodine, that is aiming to be the first approved nasal spray medicine targeting the virus that is the cause of the common cold.
Firebrick has completed Phase 1, 2 and 3 trials and is planning a second phase 3 trial starting in 2022.
They are also planning a Phase 2 trial designed to assess Nasodine as a potential treatment for Covid positive patients.
